Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Luminus Management Enters Into Share Repurchase Agreement With Calpine Corporation (CPN); Sells A Third Of Its Holding

Luminus Management, run by Jonathan Barrett and Paul Segal, has sold a considerable share of its investment in Calpine Corporation (NYSE:CPN). At the end of April, Luminus had reported a massive increase in its holding of the stock to more than 41 million shares. Now, Barrett and Segal have considerably reduced their investment to 27.9 million shares, which give them control over 6.6% of the company’s common stock. The 13.2 million shares were sold in accordance with a Share Repurchase Agreement between Calpine Corporation (NYSE:CPN) and LSP Cal Holdings I, LLC, one of the funds run by Luminus Management, at a price of $23.57 apiece.

Calpine Corporation (NYSE:CPN)

Lee Ainslie is a fan of Calpine Corporation (NYSE:CPN), having increased his fund’s stake in the company by 19% during the first quarter of 2014. Maverick Capital has reported ownership of approximately 11.2 million shares in its latest 13F filing. Peter Adam Hochfelder, the manager of Brahman Capital, also likes this stock, having initiated a new position that amassed 10.3 million shares. Harris Associates, managed by Natixis Global Asset Management, holds 11.8 million shares, up 11% during the first three months of 2014.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!